Uncategorized

Gains in issuance, forbearance and changing callability

admin | November 30, 2018

This document is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt research reports prepared for retail investors. This material does not constitute research.

The new non-agency MBS market looks poised to grow significantly next year, with a big boost potentially coming from a flow of loans out of the agency market and into private securitization. Changes at the top of the house at Federal Housing Finance Agency could accelerate the flow. Forbearance stands to get more focus as an underappreciated source of return in legacy RMBS. And the landscape of called legacy RMBS deals stands to shift, too, as interest rates edge higher and loan values fall.

***

Drivers of issuance in 2019

For the first time in a decade, issuance of new private-label RMBS in 2018 will eclipse runoff of the legacy market. And prospects for an encore in 2019 look strong. Prime jumbo issuance has made up 60% of issuance year-to-date. Expanded prime and non-QM transactions have each made up roughly 20% of issuance year to date. Total issuance should come in at roughly $30 billion for this year and could increase 50% or more next year.

Increased issuance will likely hinge on a handful of factors but potentially the most meaningful is the continued flow of GSE-eligible loans into private-label execution. Based on an analysis of one month’s 30-year fixed-rate GSE production, roughly 10% would have had a better private-label execution. Given current trends in issuance, it’s not surprising that jumbo conforming and investor loans made up the overwhelming majority of collateral that would have had a more favorable PLS execution. Private-label execution would have been better on roughly three quarters of investor and 40% of conforming jumbo originations. The improvement in execution potentially is significant. Based on estimated subordination and clearing levels in a private-label deal, private-label execution looks approximately $1-16 better than agency execution on certain jumbo conforming loans (Exhibit 1).

Exhibit 1: Conforming jumbo private-label execution may be 1.5 point better than GSE

Note: We estimate that a 760 FICO, 70 LTV, 30 DTI loan would require roughly 8% credit enhancement to AAA and a 4.0% pass through would trade roughly 1 5/8 to 1/3/4 points back of TBA FNCL 4.0%s. We then size the rest of the capital structure consistent with current published rating agency subordination levels. Assuming a 4.75% note rate we strip off a 25 bp base MSR strip and a AAA IO which we price to a 4 times coupon multiple. We then take that same loan strip a 65 bp guarantee fee, 25 bp LLPA, 25 bp base servicing strip, 10 bp excess servicing strip valued at a 4 times coupon multiple and deliver the loan into FNJMCK 3.5% execution at roughly one point back of TBA. Source: Amherst Pierpont, As of November 27, 2018

A 50% bump to private-label issuance may be conservative if 10% of monthly conventional originations flow into non-agency securitizations. And that 10% is potentially poised to increase further based on pending changes at the Federal Housing Finance Agency. Current FHFA Director Mel Watt will leave office in January next year. Although it’s unclear at this time who the president will nominate, there is significant conjecture that the next director will take measures to reduce the size of the GSEs footprint. A recent Inside Mortgage Finance article identified a leading candidate as administration economist Mark Calabria, who has expressed anti-GSE sentiment in the past. If appointed, it’s plausible that he could increase guarantee fees the enterprises charge. An increase in fees could further skew more agency eligible production into private-label execution.

Forbearance – more than you may think

It’s possible that the equivalent of 10% of the outstanding legacy universe or $30 billion is forbearance inaccurately reported as losses. A growing amount of loans with no forborne principal attached has received principal recoveries in excess of the reported loan balance when the loan leaves the trust. These recoveries are a function of one of two scenarios. In some cases, the forbearance has been misrepresented as an outstanding prior loss, which is reversed in part or whole when the loan leaves the trust through either prepayment or liquidation. In other cases, loans show recoveries on balance reductions never recorded as a loss. Based on capital structure leverage, these recoveries can drive bond prices up 50% or more. Given the scale of the opportunity and potential impact on bond prices, this phenomenon may be the biggest source of alpha in the legacy market or all residential credit for 2019.

To date, an estimated $16 billion in loans with more than $5 billion of potentially unreported forbearance have liquidated. Recoveries rates have averaged 7% on these unreported balances. We estimate that roughly a quarter of the outstanding PLS universe has $31 billion in outstanding unreported forbearance. Model projections predict that 84% of these loans will either prepay or pay in full at maturity suggesting that some or all of $25 billion in unreported forbearance could be recovered when those loans prepay or mature.

There is likely some skepticism among market participants that such a large amount of potential principal recovery could go unnoticed for so long. But unreported forbearance recoveries are a real cash flow event and they continue to occur. In order to estimate the amount of unreported forbearance, we observe abatements on all loans where there is no reported forbearance and therefore no forbearance recovery when the loans leave the pool. We capture both the total recorded loss and balance reductions on loans that abate and then look for any reversal of those losses or balance reductions when the loans leave the pool. In trusts where we see reversals of past losses or balance reductions, we add the outstanding recorded losses and balance reductions as potential unreported forbearance.

An Example: ARSI 2006-M3

One of many specific examples of this phenomenon is ARSI 2006-M3. Over the life of the deal we observe $63 million of loans leave the pool with no reported forbearance. Those loans had $4.2 million in reported outstanding losses and just under $3 million in reported balance reductions. Those loans experienced a 13% recovery on past losses and a 17.8% recovery on previous balance reductions. The deal has an additional $56 million in outstanding losses and $30 million in reported balance reductions, and more than half of those have been recently converted to outstanding reported forbearance in the amount of $45.8 million.

Exhibit 2: Liquidated vs outstanding unreported forebearance – ARSI 2006-M3

Source: Intex, LP, Amherst Pierpont

While there are some discernible patterns in unreported forbearance recoveries, they can vary significantly across shelves and trusts. Additionally, larger pockets of unreported forbearance appear to be localized to certain trustees. While the opportunity looks significant it is by no means uniform across the legacy universe. The ability to identify shelves and bonds that have disproportionate upside to these recoveries may be the biggest potential source of alpha in mortgage credit next year.

What’s the call?

While Fed Chairman Powell this week may have left market participants believing that we are close to the end of the tightening cycle, interest rate risk still exists in the legacy market. Options on collateral also have interest rate duration as the value of the option falls if rising rates reduce the value of the collateral. As a result of this, the profile of deals that get called may shift if interest rates continue to rise, potentially shifting the mix away from higher WAC fixed rate collateral to higher margin post-reset hybrids.

We cut the legacy universe into one year duration buckets by shelf and average collateral price assuming a 4% yield-to-price in an effort to ascertain which shelves have a large population of currently callable collateral and how susceptible that collateral’s price is to higher rates. Based on this methodology it appears that even with a material backup in rates, CWL deals should remain callable given an average collateral price north of 104 and a duration of just over two years. Conversely, the value of the call option should likely be discounted on shelves trading closer to par whose collateral has more rate duration like the BSARM and CWALT shelves.

Exhibit 3: Weighing the value of the call option against higher rates

Source: Amherst Pierpont

Valuing the call option in legacy space is a complex and muti-variable analysis. While the always-performing and re-performing loans will be called at par, the non-performers will be assigned a lower and less transparent valuation. Additional considerations include the value associated with recovering outstanding advances, which are likely currently being financed and the potential value associated with forborne principal. Even with those considerations in mind, it is impossible to know the effective strike price of the call if the owner of the call rights owns discount bonds which would effectively reduce the strike price below par.

This ambiguity was less pronounced against the backdrop of lower rates as seasoned higher WAC, fixed rate subprime deals with relatively small non-performing buckets had a significantly higher likelihood of being called than other profiles. Against higher rates the picture becomes even less clear but the call option will likely remain significantly more valuable for certain shelves and less so for others.

admin
jkillian@apsec.com
john.killian@santander.us 1 (646) 776-7714

This material is intended only for institutional investors and does not carry all of the independence and disclosure standards of retail debt research reports. In the preparation of this material, the author may have consulted or otherwise discussed the matters referenced herein with one or more of SCM’s trading desks, any of which may have accumulated or otherwise taken a position, long or short, in any of the financial instruments discussed in or related to this material. Further, SCM may act as a market maker or principal dealer and may have proprietary interests that differ or conflict with the recipient hereof, in connection with any financial instrument discussed in or related to this material.

This message, including any attachments or links contained herein, is subject to important disclaimers, conditions, and disclosures regarding Electronic Communications, which you can find at https://portfolio-strategy.apsec.com/sancap-disclaimers-and-disclosures.

Important Disclaimers

Copyright © 2025 Santander US Capital Markets LLC and its affiliates (“SCM”). All rights reserved. SCM is a member of FINRA and SIPC. This material is intended for limited distribution to institutions only and is not publicly available. Any unauthorized use or disclosure is prohibited.

In making this material available, SCM (i) is not providing any advice to the recipient, including, without limitation, any advice as to investment, legal, accounting, tax and financial matters, (ii) is not acting as an advisor or fiduciary in respect of the recipient, (iii) is not making any predictions or projections and (iv) intends that any recipient to which SCM has provided this material is an “institutional investor” (as defined under applicable law and regulation, including FINRA Rule 4512 and that this material will not be disseminated, in whole or part, to any third party by the recipient.

The author of this material is an economist, desk strategist or trader. In the preparation of this material, the author may have consulted or otherwise discussed the matters referenced herein with one or more of SCM’s trading desks, any of which may have accumulated or otherwise taken a position, long or short, in any of the financial instruments discussed in or related to this material. Further, SCM or any of its affiliates may act as a market maker or principal dealer and may have proprietary interests that differ or conflict with the recipient hereof, in connection with any financial instrument discussed in or related to this material.

This material (i) has been prepared for information purposes only and does not constitute a solicitation or an offer to buy or sell any securities, related investments or other financial instruments, (ii) is neither research, a “research report” as commonly understood under the securities laws and regulations promulgated thereunder nor the product of a research department, (iii) or parts thereof may have been obtained from various sources, the reliability of which has not been verified and cannot be guaranteed by SCM, (iv) should not be reproduced or disclosed to any other person, without SCM’s prior consent and (v) is not intended for distribution in any jurisdiction in which its distribution would be prohibited.

In connection with this material, SCM (i) makes no representation or warranties as to the appropriateness or reliance for use in any transaction or as to the permissibility or legality of any financial instrument in any jurisdiction, (ii) believes the information in this material to be reliable, has not independently verified such information and makes no representation, express or implied, with regard to the accuracy or completeness of such information, (iii) accepts no responsibility or liability as to any reliance placed, or investment decision made, on the basis of such information by the recipient and (iv) does not undertake, and disclaims any duty to undertake, to update or to revise the information contained in this material.

Unless otherwise stated, the views, opinions, forecasts, valuations, or estimates contained in this material are those solely of the author, as of the date of publication of this material, and are subject to change without notice. The recipient of this material should make an independent evaluation of this information and make such other investigations as the recipient considers necessary (including obtaining independent financial advice), before transacting in any financial market or instrument discussed in or related to this material.

Important disclaimers for clients in the EU and UK

This publication has been prepared by Trading Desk Strategists within the Sales and Trading functions of Santander US Capital Markets LLC (“SanCap”), the US registered broker-dealer of Santander Corporate & Investment Banking. This communication is distributed in the EEA by Banco Santander S.A., a credit institution registered in Spain and authorised and regulated by the Bank of Spain and the CNMV. Any EEA recipient of this communication that would like to affect any transaction in any security or issuer discussed herein should do so with Banco Santander S.A. or any of its affiliates (together “Santander”). This communication has been distributed in the UK by Banco Santander, S.A.’s London branch, authorised by the Bank of Spain and subject to regulatory oversight on certain matters by the Financial Conduct Authority (FCA) and the Prudential Regulation Authority (PRA).

The publication is intended for exclusive use for Professional Clients and Eligible Counterparties as defined by MiFID II and is not intended for use by retail customers or for any persons or entities in any jurisdictions or country where such distribution or use would be contrary to local law or regulation.

This material is not a product of Santander´s Research Team and does not constitute independent investment research. This is a marketing communication and may contain ¨investment recommendations¨ as defined by the Market Abuse Regulation 596/2014 ("MAR"). This publication has not been prepared in accordance with legal requirements designed to promote the independence of research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. The author, date and time of the production of this publication are as indicated herein.

This publication does not constitute investment advice and may not be relied upon to form an investment decision, nor should it be construed as any offer to sell or issue or invitation to purchase, acquire or subscribe for any instruments referred herein. The publication has been prepared in good faith and based on information Santander considers reliable as of the date of publication, but Santander does not guarantee or represent, express or implied, that such information is accurate or complete. All estimates, forecasts and opinions are current as at the date of this publication and are subject to change without notice. Unless otherwise indicated, Santander does not intend to update this publication. The views and commentary in this publication may not be objective or independent of the interests of the Trading and Sales functions of Santander, who may be active participants in the markets, investments or strategies referred to herein and/or may receive compensation from investment banking and non-investment banking services from entities mentioned herein. Santander may trade as principal, make a market or hold positions in instruments (or related derivatives) and/or hold financial interest in entities discussed herein. Santander may provide market commentary or trading strategies to other clients or engage in transactions which may differ from views expressed herein. Santander may have acted upon the contents of this publication prior to you having received it.

This publication is intended for the exclusive use of the recipient and must not be reproduced, redistributed or transmitted, in whole or in part, without Santander’s consent. The recipient agrees to keep confidential at all times information contained herein.